BACKGROUND: We performed a meta-analysis to systematically measure efficacy and safety of vasopressin receptor antagonists (VRAs) tested in randomized controlled trials for treatment of hyponatremia. METHODS: MEDLINE, ClinicalTrials.gov, and scientific abstracts were searched without language restriction. Two authors independently screened citations and extracted data on patient characteristics, quality of reports, and efficacy and safety endpoints. RESULTS: Eleven trials were identified (1094 patients). By meta-analysis, VRAs achieved a net increase in serum sodium concentration ([Na(+)](serum)) relative to placebo of 3.3 mEq/L at day 1 (95% confidence interval [CI], 2.7-3.8), and 4.2 mEq/L at day 2 (95% CI, 3.6-4.8), persisting at days 3-5. Larger net increases in [Na(+)](serum) at days 1-4 were observed in euvolemic hyponatremia and with higher doses. VRAs induced a net increase in effective water clearance relative to placebo of 1244 mL at day 1 (95% CI, 920-1567), persisting at days 2 and 4. VRAs were associated with odds ratios of 3.0 for overly rapid correction of [Na(+)](serum) (P <.001), 7.8 for development of hypernatremia (P <.001), 3.3 for thirst development (P <.001), and 2.2 for postural hypotension (P=.04). CONCLUSIONS: Short-term use of VRAs in treating hyponatremia was successful at raising [Na(+)](serum). Additional experience is required to guide their optimal use and minimize safety concerns.
BACKGROUND: We performed a meta-analysis to systematically measure efficacy and safety of vasopressin receptor antagonists (VRAs) tested in randomized controlled trials for treatment of hyponatremia. METHODS: MEDLINE, ClinicalTrials.gov, and scientific abstracts were searched without language restriction. Two authors independently screened citations and extracted data on patient characteristics, quality of reports, and efficacy and safety endpoints. RESULTS: Eleven trials were identified (1094 patients). By meta-analysis, VRAs achieved a net increase in serum sodium concentration ([Na(+)](serum)) relative to placebo of 3.3 mEq/L at day 1 (95% confidence interval [CI], 2.7-3.8), and 4.2 mEq/L at day 2 (95% CI, 3.6-4.8), persisting at days 3-5. Larger net increases in [Na(+)](serum) at days 1-4 were observed in euvolemic hyponatremia and with higher doses. VRAs induced a net increase in effective water clearance relative to placebo of 1244 mL at day 1 (95% CI, 920-1567), persisting at days 2 and 4. VRAs were associated with odds ratios of 3.0 for overly rapid correction of [Na(+)](serum) (P <.001), 7.8 for development of hypernatremia (P <.001), 3.3 for thirst development (P <.001), and 2.2 for postural hypotension (P=.04). CONCLUSIONS: Short-term use of VRAs in treating hyponatremia was successful at raising [Na(+)](serum). Additional experience is required to guide their optimal use and minimize safety concerns.
Authors: Victor F Seabra; Sami Alobaidi; Ethan M Balk; Alan H Poon; Bertrand L Jaber Journal: Clin J Am Soc Nephrol Date: 2010-07-29 Impact factor: 8.237
Authors: Mihai Gheorghiade; Wendy A Gattis; Christopher M O'Connor; Kirkwood F Adams; Uri Elkayam; Alejandro Barbagelata; Jalal K Ghali; Raymond L Benza; Frank A McGrew; Marc Klapholz; John Ouyang; Cesare Orlandi Journal: JAMA Date: 2004-04-28 Impact factor: 56.272
Authors: Joseph G Verbalis; Julianna Barsony; Yoshihisa Sugimura; Ying Tian; Douglas J Adams; Elizabeth A Carter; Helaine E Resnick Journal: J Bone Miner Res Date: 2010-03 Impact factor: 6.741
Authors: Luigi Mario Castello; Marco Baldrighi; Alice Panizza; Ettore Bartoli; Gian Carlo Avanzi Journal: Intern Emerg Med Date: 2016-07-21 Impact factor: 3.397
Authors: Evi V Nagler; Maria C Haller; Wim Van Biesen; Raymond Vanholder; Jonathan C Craig; Angela C Webster Journal: Cochrane Database Syst Rev Date: 2018-06-28
Authors: Michele Umbrello; Elena S Mantovani; Paolo Formenti; Claudia Casiraghi; Davide Ottolina; Martina Taverna; Angelo Pezzi; Giovanni Mistraletti; Gaetano Iapichino Journal: Ann Intensive Care Date: 2016-01-04 Impact factor: 6.925
Authors: Francisco Herrera-Gómez; Diana Monge-Donaire; Carlos Ochoa-Sangrador; Juan Bustamante-Munguira; Eric Alamartine; F Javier Álvarez Journal: J Clin Med Date: 2018-09-07 Impact factor: 4.241